| Label-free detection of biomolecular interactions using BioLayer interferometry for kinetic characterization J Concepcion, K Witte, C Wartchow, S Choo, D Yao, H Persson, J Wei, ... Combinatorial chemistry & high throughput screening 12 (8), 791-800, 2009 | 388 | 2009 |
| Luminescent oxygen channeling assay (LOCI): sensitive, broadly applicable homogeneous immunoassay method EF Ullman, H Kirakossian, AC Switchenko, J Ishkanian, M Ericson, ... Clinical chemistry 42 (9), 1518-1526, 1996 | 313 | 1996 |
| A novel antiangiogenesis therapy using an integrin antagonist or anti–Flk-1 antibody coated 90Y-labeled nanoparticles L Li, CA Wartchow, SN Danthi, Z Shen, N Dechene, J Pease, HS Choi, ... International Journal of Radiation Oncology* Biology* Physics 58 (4), 1215-1227, 2004 | 210 | 2004 |
| Method of reducing collateral flow in a portion of a lung N Aronson, C Wartchow, G Gong US Patent App. 11/153,233, 2005 | 175 | 2005 |
| Biosensor-based small molecule fragment screening with biolayer interferometry CA Wartchow, F Podlaski, S Li, K Rowan, X Zhang, D Mark, KS Huang Journal of computer-aided molecular design 25 (7), 669-676, 2011 | 150 | 2011 |
| Lung device with sealing features E McGurk, R Dieck, M Mathis, C Wartchow US Patent 7,766,891, 2010 | 149 | 2010 |
| Targeted multivalent macromolecules S Danthi, M Bednarski, C Wartchow, H Choi US Patent App. 10/159,596, 2003 | 129 | 2003 |
| Metal impurities cause false positives in high-throughput screening campaigns JC Hermann, Y Chen, C Wartchow, J Menke, L Gao, SK Gleason, ... ACS medicinal chemistry letters 4 (2), 197-200, 2013 | 112 | 2013 |
| Pleural effusion treatment device, method and material E McGurk, R Dieck, C Wartchow, G Gong, J Balceta US Patent 7,766,938, 2010 | 100 | 2010 |
| New carbohydrate-based materials for the stabilization of proteins P Wang, TG Hill, CA Wartchow, ME Huston, LM Oehler, MB Smith, ... Journal of the American Chemical Society 114 (1), 378-380, 1992 | 91 | 1992 |
| Deconstruction of a nutlin: dissecting the binding determinants of a potent protein–protein interaction inhibitor DC Fry, C Wartchow, B Graves, C Janson, C Lukacs, U Kammlott, ... ACS medicinal chemistry letters 4 (7), 660-665, 2013 | 66 | 2013 |
| Targeted therapeutic agents K Li, M Bednarski, C Wartchow, J Pease, N DeChene, J Trulson, ZM Shen US Patent App. 09/976,254, 2002 | 56 | 2002 |
| Targeted therapeutic lipid constructs K Brunke, C Wartchow, J Cleland US Patent App. 10/401,280, 2004 | 41 | 2004 |
| Targeted multivalent macromolecules C Wartchow, N DeChene, J Pease, Z Shen, J Trulson, M Bednarski, ... US Patent App. 10/158,777, 2003 | 41 | 2003 |
| Carbohydrate protease conjugates: Stabilized proteases for peptide synthesis CA Wartchow, P Wang, MD Bednarski, MR Callstrom The Journal of Organic Chemistry 60 (7), 2216-2226, 1995 | 41 | 1995 |
| Targeted therapeutic lipid constructs having cell surface targets C Wartchow, J Pease, Z Shen US Patent App. 10/262,576, 2003 | 40 | 2003 |
| Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapy S Bonazzi, E d’Hennezel, REJ Beckwith, L Xu, A Fazal, A Magracheva, ... Cell Chemical Biology 30 (3), 235-247. e12, 2023 | 33 | 2023 |
| Homogeneous immunoassays EF Ullman The immunoassay handbook, 67-87, 2013 | 31 | 2013 |
| Inhibition of prenylated KRAS in a lipid environment JM Jansen, C Wartchow, W Jahnke, S Fong, T Tsang, K Pfister, ... PLoS One 12 (4), e0174706, 2017 | 28 | 2017 |
| Two distinct mechanisms of inhibition of LpxA acyltransferase essential for lipopolysaccharide biosynthesis W Han, X Ma, CJ Balibar, CM Baxter Rath, B Benton, A Bermingham, ... Journal of the American Chemical Society 142 (9), 4445-4455, 2020 | 26 | 2020 |
